8-K: Amgen Reports Strong Q2 2026 Results, Revenue Up 10%

Amgen announced robust second quarter 2026 financial results, with total revenues climbing 10% year-over-year to $10.1 billion, driven by strong product sales growth.

Summary

• Amgen reported a 10% increase in total revenues for the second quarter of 2026, reaching $10.1 billion compared to the second quarter of 2025.
• Product sales grew by 9%, fueled by volume increases, with 22 products achieving at least double-digit sales growth.
• GAAP earnings per share (EPS) saw a significant increase of 65%, rising from $2.65 to $4.37.
• GAAP operating income grew from $2.7 billion to $3.5 billion, with the operating margin improving to 36.8%.
• Non-GAAP EPS increased by 4% to $6.29, and non-GAAP operating income rose to $4.6 billion.
• Free cash flow generation was strong, reaching $3.5 billion in Q2 2026, a substantial increase from $1.9 billion in Q2 2025.
• The company reaffirmed its full-year 2026 guidance, expecting total revenues between $38.2 billion and $39.4 billion.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and significant increases in key product sales, alongside a robust outlook for the full year 2026.

Positives

• Total revenues increased by 10% to $10.1 billion in Q2 2026.
• Product sales grew by 9% year-over-year, driven by volume.
• Twenty-two products achieved at least double-digit sales growth.
• Seventeen products are annualizing at over $1 billion based on Q2 sales.
• GAAP EPS increased by 65% to $4.37.
• GAAP operating income increased to $3.5 billion, with a margin of 36.8%.
• Non-GAAP EPS grew 4% to $6.29.
• Free cash flow more than doubled to $3.5 billion.
• Repatha sales increased 37% to $953 million.
• EVENITY sales increased 38% to $714 million.
• UPLIZNA sales surged 90% to $335 million.
• TEZSPIRE sales increased 42% to $486 million.
• PAVBLU sales increased 121% to $287 million.
• IMDELLTRA sales increased 115% to $288 million.
• Full-year 2026 revenue guidance remains strong at $38.2 billion to $39.4 billion.

Negatives

• Prolia sales decreased 32% to $759 million due to biosimilar competition.
• Otezla sales decreased 21% to $491 million, driven by lower net selling price and volume.
• Enbrel sales decreased 4% to $580 million, impacted by lower net selling price due to the Inflation Reduction Act and increased 340B Program mix.
• XGEVA sales decreased 34% to $352 million due to biosimilar competition.
• MVASI sales decreased 20% to $153 million, driven by lower net selling price and volume.
• Non-GAAP operating margin decreased slightly by 0.5 percentage points to 48.4%.
• The company is engaging with the FDA regarding a potential voluntary withdrawal of TAVNEOS from the U.S. market.

Risks

• Prolia and XGEVA sales are declining due to the launch of biosimilars.
• Enbrel sales are impacted by U.S. Medicare Part D price setting under the Inflation Reduction Act and an increased 340B Program mix.
• Otezla sales are affected by a lower net selling price and volume.
• The company is in discussions with the FDA regarding a potential voluntary withdrawal of TAVNEOS from the U.S. market.
• Future development of AMG 513 will be discontinued.
• Enrollment in subcutaneous blinatumomab studies has paused due to a partial clinical hold by the FDA.

Future Outlook

For the full year 2026, Amgen expects total revenues to be in the range of $38.2 billion to $39.4 billion. GAAP EPS is projected between $15.80 and $17.08, with a GAAP tax rate of 14.5% to 16.0%. Non-GAAP EPS is forecasted between $22.30 and $23.50, with a non-GAAP tax rate of 15.0% to 16.5%. Capital expenditures are expected to be approximately $2.6 billion, and share repurchases are not expected to exceed $3.0 billion.

Management Comments

• "Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales."
• "As we expand the potential of our existing medicines through new indications and advance the next wave of pipeline molecules through Phase 3, we remain confident in our ability to deliver growth well into the next decade."

Industry Context

StockSavvy.ai notes that Amgen's performance in Q2 2026 reflects a dynamic pharmaceutical landscape. The strong growth in key products like Repatha and EVENITY, alongside the significant revenue contribution from newer drugs like UPLIZNA and IMDELLTRA, highlights successful product development and market penetration. However, the impact of biosimilar competition on established products like Prolia and XGEVA, and pricing pressures from legislation like the Inflation Reduction Act on Enbrel, are significant headwinds that the company is navigating.

Comparison to Industry Standards

• Amgen's total revenue growth of 10% in Q2 2026 is robust compared to the broader pharmaceutical industry average, which has seen more moderate growth in recent quarters.
• The 9% product sales growth, driven by volume, is a positive indicator of market demand for Amgen's portfolio, outperforming many competitors facing patent cliffs or slower market adoption.
• The significant increase in GAAP EPS (65%) suggests strong operational leverage or favorable one-time items, though the non-GAAP EPS growth (4%) provides a more normalized view of operational profitability.
• Free cash flow generation of $3.5 billion is substantial and indicates strong financial health, allowing for continued investment in R&D and potential strategic acquisitions.
• The company's pipeline, particularly with the extensive Phase 3 studies for MariTide, positions it to compete in the growing obesity and metabolic disease market, a key area of focus for many large pharmaceutical and biotech firms.

Legal Proceedings

• The company continues to engage with the FDA regarding the Center for Drug Evaluation and Research's request to voluntarily withdraw TAVNEOS from the U.S. market. The company requested a hearing and submitted supporting materials on July 23, 2026.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, increased EPS, and robust free cash flow, alongside reaffirmed full-year guidance. Potential negative impact from ongoing biosimilar competition and regulatory discussions around TAVNEOS.
• Employees: Continued investment in R&D and pipeline advancement suggests ongoing opportunities. However, any restructuring or cost-saving initiatives could impact employment.
• Customers/Patients: Access to key medicines like Repatha, EVENITY, and UPLIZNA is supported by strong sales. However, pricing pressures and biosimilar competition may affect affordability and availability of certain treatments.
• Creditors: Strong financial performance and free cash flow generation are positive for creditors, indicating the company's ability to service its debt.

Next Steps

• Continue advancing the extensive Phase 3 development program for MariTide across multiple indications.
• Initiate three Phase 3 studies of MariTide in people living with Type 2 diabetes in 2026.
• Present further data from VESALIUS-CV study analyses at the European Society of Cardiology (ESC) Congress in August 2026.
• Initiate a Phase 3 study of UPLIZNA in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in H2 2026 H1 2027.
• Complete two Phase 3 studies of dazodalibep in Sjögren's disease in H2 2026.
• Complete a Phase 3 study of TEZSPIRE in patients with eosinophilic esophagitis in H2 2026.
• Discuss new data from the DeLLphi-309 study with regulators and present detailed results at an upcoming medical congress.
• Continue to engage with the FDA regarding TAVNEOS.

Key Dates

Recommendation

Amgen delivered strong Q2 results with significant revenue and EPS growth, and reaffirmed its full-year guidance. However, ongoing challenges from biosimilar competition on key products like Prolia and XGEVA, coupled with pricing pressures from legislation and regulatory discussions around TAVNEOS, warrant a cautious approach. While the pipeline, particularly for obesity, is promising, these headwinds suggest a 'hold' rating until greater clarity emerges on the impact of these factors and the success of new pipeline drugs.

Keywords

Amgen, Q2 2026 Earnings, Biotechnology, Pharmaceuticals, Revenue Growth, Product Sales, Pipeline Update, Financial Results